Iovance Biotherapeutics (NASDAQ:IOVA) Stock Sees Unusually High Call Option Buying

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was the recipient of some unusual options trading on Thursday. Stock investors acquired 28,173 call options on the stock. This represents an increase of 70% compared to the average daily volume of 16,565 call options.

Iovance Biotherapeutics Stock Performance

Shares of Iovance Biotherapeutics stock opened at $9.56 on Friday. Iovance Biotherapeutics has a one year low of $1.76 and a one year high of $15.37. The company has a market capitalization of $4.33 billion, a PE ratio of -13.10 and a beta of 0.76. The company has a 50-day simple moving average of $11.38 and a two-hundred day simple moving average of $5.79.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. The business had revenue of $99.31 million during the quarter, compared to the consensus estimate of $87.83 million. During the same quarter in the prior year, the firm posted ($0.33) earnings per share. The company’s revenue was up 65.7% compared to the same quarter last year. On average, equities analysts predict that Iovance Biotherapeutics will post -0.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Iovance Biotherapeutics

A number of large investors have recently added to or reduced their stakes in the company. NorthCrest Asset Manangement LLC lifted its stake in Iovance Biotherapeutics by 5.4% in the third quarter. NorthCrest Asset Manangement LLC now owns 13,735 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 707 shares during the period. Arcataur Capital Management LLC grew its stake in Iovance Biotherapeutics by 3.6% in the 3rd quarter. Arcataur Capital Management LLC now owns 28,600 shares of the biotechnology company’s stock valued at $424,000 after acquiring an additional 1,000 shares during the period. Krilogy Financial LLC boosted its stake in Iovance Biotherapeutics by 6.6% during the 3rd quarter. Krilogy Financial LLC now owns 16,662 shares of the biotechnology company’s stock worth $243,000 after purchasing an additional 1,032 shares during the last quarter. Sequoia Financial Advisors LLC boosted its position in shares of Iovance Biotherapeutics by 5.4% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 32,957 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 1,691 shares during the last quarter. Finally, Valley National Advisers Inc. acquired a new position in Iovance Biotherapeutics in the third quarter valued at about $38,000. 77.03% of the stock is owned by institutional investors and hedge funds.

More Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported a 24.6% objective response rate among 69 patients with nonsquamous mNSCLC, consistent with previously reported results. The company said the data support a planned supplemental biologics license application for lifileucel in this indication in 2027. Iovance Reports Updated IOV-LUN-202 Results
• Positive Sentiment: The KRAS wild-type subgroup posted a 43.3% response rate versus 11.4% in KRAS-mutant disease, while a novel biomarker-enriched subgroup achieved a 59.1% response rate. Iovance plans to begin the registrational-intent POSITILITY study in November 2026, potentially improving the precision-TIL strategy. Iovance Positive Lifileucel Data Transcript
• Positive Sentiment: Earlier reports of encouraging lifileucel activity in melanoma, undifferentiated pleomorphic sarcoma and liposarcoma reinforce the broader commercial potential of Iovance’s TIL platform. Lifileucel Shows 50% Response Rate
• Neutral Sentiment: Unusual options activity preceded the readout, with 28,173 call options traded—about 70% above typical volume—indicating elevated speculative interest but not necessarily a durable change in fundamentals.
• Negative Sentiment: The stock plunged after the updated lung-cancer data despite the headline 24.6% response rate. Investors appear concerned that the overall efficacy was not strong enough, and that benefit was concentrated in biomarker-defined groups, limiting the near-term addressable market. Iovance Stock Plunges After Trial Data
• Negative Sentiment: IOVA remains loss-making, and the planned 2027 filing and future POSITILITY study leave significant regulatory, clinical and execution risk before lung-cancer revenue could materialize.

Analyst Ratings Changes

IOVA has been the topic of several recent analyst reports. Wells Fargo & Company increased their price objective on shares of Iovance Biotherapeutics from $14.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, September 30th. Mizuho upped their target price on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 18th. Robert W. Baird increased their price target on shares of Iovance Biotherapeutics from $6.00 to $11.00 and gave the company a “neutral” rating in a report on Thursday, October 8th. HC Wainwright raised their price target on shares of Iovance Biotherapeutics from $9.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, September 29th. Finally, Citigroup restated an “outperform” rating on shares of Iovance Biotherapeutics in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.20.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc (NASDAQ: IOVA) is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.